Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Ensoma Closes $50M Series B Round

2023-05-16
BOSTON, MA, Ensoma today announced the closing of an extension of its Series B financing by $50 million.
Ensoma, a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million. The $50 million was contributed by new investors Kite, a Gilead Company (Nasdaq: GILD), Bioluminescence Ventures and Delos Capital and by existing investor SymBiosis. These investors joined a syndicate of leading healthcare funds to advance the development of Ensoma's Engenious™ in vivo engineered cell therapy platform and pipeline of genomic medicines for immuno-oncology, genetic disease and other therapeutic applications.

Ensoma believes the future of medicine lies within us. The company is poised to create a new therapeutic category addressing diseases that impact millions around the globe, such as cancer and autoimmunity. The Engenious™ platform can uniquely address these disorders by leveraging world-class technologies for in vivo delivery and genome engineering. The ability to target and reprogram both immune cells and self-renewing hematopoietic stem cells will create multicellular and multigenic medicines that solve potency and durability challenges limiting current approaches. Ensoma also has the potential to leapfrog therapies in well validated indications such as hemoglobinopathies and dramatically expand patient eligibility through its portable in vivo solutions. Ensoma is supported by top-tier investors, strategic partners and a passionate team committed to a bold, global vision for genomic medicine.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors